Feb 12 The fast-spreading coronavirus is
starting to disrupt testing of experimental medicines in China,
posing a threat to plans by global drugmakers that have invested
billions of dollars to harness the potential of the Asian
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse.
Pregnant women who rely on state-administered Medicaid health insurance programs are far less likely to receive recommended vaccines that could protect them and their babies, compared to those with private coverage, a study from Florida suggests.
Feb 7 AbbVie Inc on Friday forecast
full-year earnings well above Wall Street estimates, as the U.S.
drugmaker looks to new treatments and its pending acquisition of
Allergan Plc to drive growth beyond 2023, when its cash
cow Humira loses patent protection.
Cigna Corp on Thursday forecast 2020 revenue well above Wall Street estimates on Thursday, as it expects a significant increase in the number of people signing up for its government-backed Medicare Advantage health plans.
Feb 5 Humana Inc on Wednesday reported a
higher-than-expected quarterly profit on the strength of its
business that sells government-backed Medicare plans, and the
U.S. health insurer forecast 2020 revenue ahead of Wall Street
Biogen Inc said on Thursday it was preparing for the launch of its experimental treatment for Alzheimer's as the drugmaker races to become the first to bring a treatment for the memory-robbing disease to market.
Anthem Inc on Wednesday warned medical costs in 2020 would be higher than market expectations as low-margin, government-backed health plans become a bigger portion of its business, sending the U.S. insurer's shares down about 6%.
Novartis AG has secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of its value, according to a company executive and a Reuters review of public filings.